{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T18:54:53Z","timestamp":1789584893014,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00259-025-07532-4","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T08:20:10Z","timestamp":1757665210000},"page":"1608-1619","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Head-to-Head comparison of [18F]AlF-NOTA-TATE and [68Ga]Ga-DOTA-TATE PET\/CT in patients with neuroendocrine tumors: a prospective study"],"prefix":"10.1007","volume":"53","author":[{"given":"Huanhuan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shina","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingfeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yachao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanliang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouhuan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruimin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9425-5180","authenticated-orcid":false,"given":"Jinming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,12]]},"reference":[{"issue":"6","key":"7532_CR1","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s11912-022-01217-z","volume":"24","author":"EN Rizen","year":"2022","unstructured":"Rizen EN, Phan AT. Neuroendocrine tumors: A relevant clinical update. Curr Oncol Rep. 2022;24(6):703\u201314. https:\/\/doi.org\/10.1007\/s11912-022-01217-z.","journal-title":"Curr Oncol Rep"},{"issue":"12","key":"7532_CR2","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.1007\/s00259-024-06790-y","volume":"51","author":"M Liu","year":"2024","unstructured":"Liu M, Ren C, Zhang H, et al. Evaluation of the safety, biodistribution, dosimetry of [18f]alf-nota-lm3 and head-to-head comparison with [68ga]ga-dotatate in patients with well-differentiated neuroendocrine tumors: an interim analysis of a prospective trial. Eur J Nucl Med Mol Imaging. 2024;51(12):3719\u201330. https:\/\/doi.org\/10.1007\/s00259-024-06790-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7532_CR3","doi-asserted-by":"publisher","unstructured":"Adnan A, Basu S. Somatostatin receptor targeted pet-ct and its role in the management and theranostics of gastroenteropancreatic neuroendocrine neoplasms. Diagnostics (Basel). 2023;13(13). https:\/\/doi.org\/10.3390\/diagnostics13132154.","DOI":"10.3390\/diagnostics13132154"},{"key":"7532_CR4","doi-asserted-by":"publisher","unstructured":"Asmundo L, Rizzetto F, Blake M, et al. Advancements in neuroendocrine neoplasms: imaging and future frontiers. J Clin Med. 2024;13(11). https:\/\/doi.org\/10.3390\/jcm13113281.","DOI":"10.3390\/jcm13113281"},{"issue":"6","key":"7532_CR5","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1097\/mnm.0000000000000106","volume":"35","author":"P Mapelli","year":"2014","unstructured":"Mapelli P, Tam HH, Sharma R, et al. Frequency and significance of physiological versus pathological uptake of 68ga-dotatate in the pancreas: validation with morphological imaging. Nucl Med Commun. 2014;35(6):613\u20139. https:\/\/doi.org\/10.1097\/mnm.0000000000000106.","journal-title":"Nucl Med Commun"},{"issue":"3","key":"7532_CR6","doi-asserted-by":"publisher","first-page":"416","DOI":"10.2967\/jnumed.123.266601","volume":"65","author":"S Dubash","year":"2024","unstructured":"Dubash S, Barwick TD, Kozlowski K, et al. Somatostatin receptor imaging with [18f]fet-\u03b2ag-toca pet\/ct and [68ga]ga-dota-peptide pet\/ct in patients with neuroendocrine tumors: A prospective, phase 2 comparative study. J Nucl Med. 2024;65(3):416\u201322. https:\/\/doi.org\/10.2967\/jnumed.123.266601.","journal-title":"J Nucl Med"},{"issue":"2","key":"7532_CR7","doi-asserted-by":"publisher","first-page":"204","DOI":"10.2967\/jnumed.122.264860","volume":"64","author":"TA Hope","year":"2023","unstructured":"Hope TA, Allen-Auerbach M, Bodei L, et al. Snmmi procedure standard\/eanm practice guideline for Sstr pet: imaging neuroendocrine tumors. J Nucl Med. 2023;64(2):204\u201310. https:\/\/doi.org\/10.2967\/jnumed.122.264860.","journal-title":"J Nucl Med"},{"key":"7532_CR8","doi-asserted-by":"publisher","unstructured":"Fersing C, Bouhlel A, Cantelli C, et al. A comprehensive review of non-covalent radiofluorination approaches using aluminum [(18)f]fluoride: will [(18)f]alf replace (68)ga for metal chelate labeling? Molecules. 2019;24(16). https:\/\/doi.org\/10.3390\/molecules24162866.","DOI":"10.3390\/molecules24162866"},{"issue":"5","key":"7532_CR9","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.7150\/thno.31806","volume":"9","author":"CM Waldmann","year":"2019","unstructured":"Waldmann CM, Stuparu AD, Van Dam RM, et al. The search for an alternative to [68ga]ga-dota-tate in neuroendocrine tumor theranostics: current state of 18f-labeled somatostatin analog development. Theranostics. 2019;9(5):1336\u201347. https:\/\/doi.org\/10.7150\/thno.31806.","journal-title":"Theranostics"},{"key":"7532_CR10","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.nucmedbio.2020.07.008","volume":"88\u201389","author":"S Lindner","year":"2020","unstructured":"Lindner S, Simmet M, Gildehaus FJ, et al. Automated production of [(18)f]sitate on a scintomics grp\u2122 platform for pet\/ct imaging of neuroendocrine tumors. Nucl Med Biol. 2020;88\u201389:86\u201395. https:\/\/doi.org\/10.1016\/j.nucmedbio.2020.07.008.","journal-title":"Nucl Med Biol"},{"issue":"8","key":"7532_CR11","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.2967\/jnumed.115.169532","volume":"57","author":"SR Dubash","year":"2016","unstructured":"Dubash SR, Keat N, Mapelli P, et al. Clinical translation of a click-labeled 18f-octreotate radioligand for imaging neuroendocrine tumors. J Nucl Med. 2016;57(8):1207\u201313. https:\/\/doi.org\/10.2967\/jnumed.115.169532.","journal-title":"J Nucl Med"},{"issue":"3","key":"7532_CR12","doi-asserted-by":"publisher","first-page":"454","DOI":"10.2967\/jnumed.109.066902","volume":"51","author":"P Laverman","year":"2010","unstructured":"Laverman P, Mcbride WJ, Sharkey RM, et al. A novel facile method of labeling octreotide with (18)f-fluorine. J Nucl Med. 2010;51(3):454\u201361. https:\/\/doi.org\/10.2967\/jnumed.109.066902.","journal-title":"J Nucl Med"},{"issue":"1","key":"7532_CR13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s41181-019-0084-1","volume":"5","author":"T Tshibangu","year":"2020","unstructured":"Tshibangu T, Cawthorne C, Serdons K, et al. Automated Gmp compliant production of [(18)f]alf-nota-octreotide. EJNMMI Radiopharm Chem. 2020;5(1):4. https:\/\/doi.org\/10.1186\/s41181-019-0084-1.","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"9","key":"7532_CR14","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1097\/RLU.0000000000004235","volume":"47","author":"ONY Lee","year":"2022","unstructured":"Lee ONY, Tan KV, Tripathi V, et al. The role of 68 Ga-DOTA-SSA PET\/CT in the management and prediction of peptide receptor radionuclide therapy response for patients with neuroendocrine tumors: A systematic review and Meta-analysis. Clin Nucl Med. 2022;47(9):781\u201393. https:\/\/doi.org\/10.1097\/RLU.0000000000004235.","journal-title":"Clin Nucl Med"},{"key":"7532_CR15","doi-asserted-by":"publisher","unstructured":"Liu H, Zhang X, Pan Y, et al. Preclinical study of a dual-target molecular probe labeled with (68)ga targeting sstr2 and fap. Pharmaceuticals (Basel). 2024;17(12). https:\/\/doi.org\/10.3390\/ph17121647.","DOI":"10.3390\/ph17121647"},{"issue":"5","key":"7532_CR16","first-page":"311","volume":"8","author":"E Pauwels","year":"2018","unstructured":"Pauwels E, Cleeren F, Bormans G, et al. Somatostatin receptor pet ligands - the next generation for clinical practice. Am J Nucl Med Mol Imaging. 2018;8(5):311\u201331.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"7532_CR17","doi-asserted-by":"publisher","unstructured":"Haeger A, Soza-Ried C, Kramer V, et al. Al[18f]f-nota-octreotide is comparable to [68ga]ga-dota-tate for pet\/ct imaging of neuroendocrine tumours in the latin-american population. Cancers. 2023;15(2). https:\/\/doi.org\/10.3390\/cancers15020439.","DOI":"10.3390\/cancers15020439"},{"key":"7532_CR18","doi-asserted-by":"publisher","unstructured":"Allott L, Dubash S, Aboagye EO. [(18)f]fet-betaag-toca: the design, evaluation and clinical translation of a fluorinated octreotide. Cancers (Basel). 2020;12(4). https:\/\/doi.org\/10.3390\/cancers12040865.","DOI":"10.3390\/cancers12040865"},{"issue":"11","key":"7532_CR19","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1007\/s00259-019-04425-1","volume":"46","author":"E Pauwels","year":"2019","unstructured":"Pauwels E, Cleeren F, Tshibangu T, et al. Al18f-nota-octreotide: first comparison with 68ga-dotatate in a neuroendocrine tumour patient. Eur J Nucl Med Mol Imaging. 2019;46(11):2398\u20139. https:\/\/doi.org\/10.1007\/s00259-019-04425-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"7532_CR20","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1097\/rlu.0000000000002578","volume":"44","author":"T Long","year":"2019","unstructured":"Long T, Yang N, Zhou M, et al. Clinical application of 18f-alf-nota-octreotide pet\/ct in combination with 18f-fdg pet\/ct for imaging neuroendocrine neoplasms. Clin Nucl Med. 2019;44(6):452\u20138. https:\/\/doi.org\/10.1097\/rlu.0000000000002578.","journal-title":"Clin Nucl Med"},{"issue":"13","key":"7532_CR21","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1007\/s00259-020-04918-4","volume":"47","author":"E Pauwels","year":"2020","unstructured":"Pauwels E, Cleeren F, Tshibangu T, et al. [(18)f]alf-nota-octreotide pet imaging: biodistribution, dosimetry and first comparison with [(68)ga]ga-dotatate in neuroendocrine tumour patients. Eur J Nucl Med Mol Imaging. 2020;47(13):3033\u201346. https:\/\/doi.org\/10.1007\/s00259-020-04918-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"7532_CR22","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1007\/s00259-019-04501-6","volume":"47","author":"H Ilhan","year":"2020","unstructured":"Ilhan H, Lindner S, Todica A, et al. Biodistribution and first clinical results of (18)f-sifalin-tate pet: A novel (18)f-labeled somatostatin analog for imaging of neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2020;47(4):870\u201380. https:\/\/doi.org\/10.1007\/s00259-019-04501-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"7532_CR23","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1007\/s00259-021-05249-8","volume":"48","author":"Q Xie","year":"2021","unstructured":"Xie Q, Liu T, Ding J, et al. Synthesis, preclinical evaluation, and a pilot clinical imaging study of [(18)f]alf-nota-jr11 for neuroendocrine neoplasms compared with [(68)ga]ga-dota-tate. Eur J Nucl Med Mol Imaging. 2021;48(10):3129\u201340. https:\/\/doi.org\/10.1007\/s00259-021-05249-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"7532_CR24","doi-asserted-by":"publisher","first-page":"7222","DOI":"10.1007\/s00330-024-10788-3","volume":"34","author":"R Ebner","year":"2024","unstructured":"Ebner R, Lohse A, Fabritius MP, et al. Validation of the standardization framework sstr-rads 1.0 for neuroendocrine tumors using the novel sstr\u2013targeting peptide [(18)f]sitate. Eur Radiol. 2024;34(11):7222\u201332. https:\/\/doi.org\/10.1007\/s00330-024-10788-3.","journal-title":"Eur Radiol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07532-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07532-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07532-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T04:43:18Z","timestamp":1769834598000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07532-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7532"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07532-4","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,12]]},"assertion":[{"value":"27 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Chinese PLA General Hospital (approval of No. S2023-209-01, Registration number of ChiCTR2300072266).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors have read this manuscript and would like to have it considered exclusively for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial interests"}}]}}